Tier 2 — strong

Neuroprotective effects of glycine for therapy of acute ischaemic stroke

Gusev EI, Skvortsova VI, Dambinova SA, Raevskiy KS, Alekseev AA, Bashkatova VG, Kovalenko AV, Kudrin VS, Yakovleva EV
Cerebrovascular diseases (Basel, Switzerland) 2000 10(1):49-60

Bibliography

PubMed
PMID 10629347
DOI
10.1159/000016025
Funding
Funding was not specified in the indexed abstract; the full funding disclosure has not been verified.
Competing interests
The accessible abstract does not establish the authors' competing interests; absence of a statement is not evidence of no conflicts.

Study snapshot

DesignRandomized controlled human intervention
ModelAdult humans
Sample200 acute ischemic-stroke patients randomized across four groups
InterventionSublingual glycine 0.5, 1 or 2 g/day versus placebo, started within 6 hours
Duration5 days treatment; clinical outcomes assessed through 30 days
EndpointsNeurological scales; Functional outcome; Mortality; Sedation

What the study showed, in plain terms

A historical acute-stroke study reported favorable findings on selected neurological and functional outcomes. It used urgent sublingual treatment under clinical supervision.

Key findings

  • Selected clinical scales favored the 1–2 g/day groups.
  • Mortality differences were described as trends rather than established survival benefit.
  • Slight sedation was recorded in nine participants.

What this study can and cannot tell us

A single older study does not establish modern stroke efficacy or change emergency-care standards.

Its acute disease setting and route do not establish benefits of chronic oral supplementation.

Related papers in the corpus

Tier 2
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments
Buchanan RW et al. · The American journal of psychiatry · 2007
Tier 2
Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia
Potkin SG et al. · The American journal of psychiatry · 1999
Tier 2
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia
Heresco-Levy U et al. · Biological psychiatry · 2004
Tier 2
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia
Heresco-Levy U et al. · Archives of general psychiatry · 1999
Tier 2
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia
Heresco-Levy U et al. · The British journal of psychiatry : the journal of mental science · 1996
Tier 2
Amelioration of negative symptoms in schizophrenia by glycine
Javitt DC et al. · The American journal of psychiatry · 1994

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction